Cameroon vs Thailand: Share of the population living with HIV receiving antiretroviral therapy
Cameroon
88.1%
in 2024
Thailand
87.7%
in 2024
Cameroon rank
26th
Thailand rank
28th
Share of the population living with HIV receiving antiretroviral therapy over time
- Cameroon
- Thailand
How they compare
Cameroon currently reports 88.1% against 87.7% in Thailand, a difference of 0.4%.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Thailand ahead.
Cameroon ranks 26th and Thailand ranks 28th of 149 countries.
Thailand has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Cameroon | Thailand | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | Thailand |
| 2000s | 4.3% | 11.5% | 7.1% | Thailand |
| 2010s | 32.5% | 52.0% | 19.6% | Thailand |
| 2020s | 78.6% | 81.4% | 2.8% | Thailand |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Cameroon or Thailand?
- Cameroon, at 88.1% against 87.7% in Thailand as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Cameroon and Thailand?
- 0.4%, with Cameroon ahead.
- How many years of comparable data are there for Cameroon and Thailand?
- 35 years are reported by both, from 1990 to 2024.
- How do Cameroon and Thailand rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Cameroon ranks 26th and Thailand ranks 28th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.